Hepatocellular Carcinoma
1,842
291
389
578
Key Insights
Highlights
Success Rate
78% trial completion
Published Results
169 trials with published results (9%)
Research Maturity
578 completed trials (31% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
8.7%
161 terminated out of 1842 trials
78.2%
-8.3% vs benchmark
11%
208 trials in Phase 3/4
29%
169 of 578 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 578 completed trials
Clinical Trials (1842)
The Safety, Efficacy, and Immune Response of Multimodal Thermal Therapy in the Treatment of Malignant Liver Tumors
Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation
Molecular Basis of Pediatric Liver Cancer
Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection
A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
IDOV-Immune for Advanced Solid Tumors
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma
TARGETed Therapy Drug MONITOring in DIGestive Oncology
Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
TheraSphere With Durvalumab and Tremelimumab for HCC
A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma
LEOPARD Prospective Validation Cohort 1
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry
LEOPARD Training and Validation Data Collection Study
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)